[Iron therapy: is it different with peritoneal dialysis compared to haemodialysis?].
This paper reviews literature data on iron replacement (loading) for peritoneal dialysis patients. The 3 main sources of clinical guidelines (American NKF-K/DOQI, European EBPG and French AFSSAPS) agree about the definition of iron deficience, but are not similar about the haemoglobin/hematocrit targets for EPO treatment, and for the route of iron administration (oral versus intravenous). Iron requirements are less in PD HD patients. That could be explained by several factors: less blood losses, preservation of a residual renal function, better digestive iron absorption due to a greater hepcidin excretion. Intravenous route for iron sucrose is more efficient than oral route. Taking into account the iron requirements for PD patients, monthly 200 mg iron sucrose infusions over 5 mn seem to be safe and sufficient for most patients.
Durand
Pierre-Yves
PY
ALTIR, hôpital de Brabois, rue du Morvan, 54504 Vandoeuvre-lès-Nancy. py.durand@chu-nancy.fr
D018798:Anemia, Iron-Deficiency / Q000209:etiology / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use; D005060:Europe; D005602:France; D006801:Humans; D007501:Iron / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000150:complications; D007677:Kidney Function Tests; D010530:Peritoneal Dialysis; D006435:Renal Dialysis; D014481:United States
D004921:Erythropoietin; D007501:Iron